BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22083486)

  • 1. Micafungin concentrations in the plasma and burn eschar of severely burned patients.
    Sasaki J; Yamanouchi S; Kudo D; Endo T; Nomura R; Takuma K; Kushimoto S; Shinozawa Y; Kishino S; Hori S; Aikawa N
    Antimicrob Agents Chemother; 2012 Feb; 56(2):1113-5. PubMed ID: 22083486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Penetration of micafungin into the burn eschar in patients with severe burns.
    Sasaki J; Yamanouchi S; Sato Y; Abe S; Shinozawa Y; Kishino S; Aikawa N; Hori S
    Eur J Drug Metab Pharmacokinet; 2014 Jun; 39(2):93-7. PubMed ID: 23771854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection.
    García-de-Lorenzo A; Luque S; Grau S; Agrifoglio A; Cachafeiro L; Herrero E; Asensio MJ; Sánchez SM; Roberts JA
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5914-21. PubMed ID: 27458229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bronchopulmonary disposition of micafungin in healthy adult volunteers.
    Nicasio AM; Tessier PR; Nicolau DP; Knauft RF; Russomanno J; Shore E; Kuti JL
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1218-20. PubMed ID: 19114675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micafungin at a standard dosage of 100 mg/day achieves adequate plasma exposure in critically ill patients with severe burn injuries.
    Asensio MJ; Sánchez M; Galván B; Herrero E; Cachafeiro L; Agrifoglio A; Perales E; Luque S; García-de-Lorenzo A
    Intensive Care Med; 2015 Feb; 41(2):371-2. PubMed ID: 25465909
    [No Abstract]   [Full Text] [Related]  

  • 6. Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients.
    Walsh TJ; Goutelle S; Jelliffe RW; Golden JA; Little EA; DeVoe C; Mickiene D; Hayes M; Conte JE
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3451-9. PubMed ID: 20439610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
    Mehta PA; Vinks AA; Filipovich A; Bleesing J; Jodele S; Jordan MB; Marsh R; Tarin R; Edwards S; Fearing D; Lawrence J; Davies SM
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1458-62. PubMed ID: 20546908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of micafungin in the tissue fluids of patients with invasive fungal infections.
    Yamada N; Kumada K; Kishino S; Mochizuki N; Ohno K; Ogura S
    J Infect Chemother; 2011 Oct; 17(5):731-4. PubMed ID: 21537970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients.
    Lempers VJ; Schouten JA; Hunfeld NG; Colbers A; van Leeuwen HJ; Burger DM; Verweij PE; Pickkers P; Brüggemann RJ
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4403-9. PubMed ID: 25963988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of micafungin area under the curve data by using peak concentration: applicability and utility in antifungal therapy.
    Srinivas NR
    Future Microbiol; 2016; 11(4):485-90. PubMed ID: 27070500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
    Boonstra JM; van der Elst KC; Veringa A; Jongedijk EM; Brüggemann RJ; Koster RA; Kampinga GA; Kosterink JG; van der Werf TS; Zijlstra JG; Touw DJ; Alffenaar JWC
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of micafungin in neonates and young infants.
    Hope WW; Smith PB; Arrieta A; Buell DN; Roy M; Kaibara A; Walsh TJ; Cohen-Wolkowiez M; Benjamin DK
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2633-7. PubMed ID: 20308367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Differential pharmacokinetic characteristics of micafungin. Experience in special populations].
    Grau Cerrato S; Luque Pardos S; Ferrández Quirante O
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():10-4. PubMed ID: 21420571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraocular penetration of intravenous micafungin in inflamed human eyes.
    Mochizuki K; Sawada A; Suemori S; Kawakami H; Niwa Y; Kondo Y; Ohkusu K; Yamada N; Ogura S; Yaguchi T; Nishimura K; Kishino S
    Antimicrob Agents Chemother; 2013 Aug; 57(8):4027-30. PubMed ID: 23689706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of liver and kidney function on migafungin disposition in patients with hematologic malignancies.
    Nakagawa Y; Ichii Y; Saeki Y; Kodama M; Kishino S; Suzuki K
    Eur J Drug Metab Pharmacokinet; 2008; 33(3):191-8. PubMed ID: 19007046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients.
    Martial LC; Ter Heine R; Schouten JA; Hunfeld NG; van Leeuwen HJ; Verweij PE; de Lange DW; Pickkers P; Brüggemann RJ
    Clin Pharmacokinet; 2017 Oct; 56(10):1197-1206. PubMed ID: 28144840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia.
    Undre NA; Stevenson P; Freire A; Arrieta A
    Pediatr Infect Dis J; 2012 Jun; 31(6):630-2. PubMed ID: 22301478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.
    Petraitiene R; Petraitis V; Hope WW; Walsh TJ
    Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S643-51. PubMed ID: 26567283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.
    Yoshikawa K; Nakazawa Y; Katsuyama Y; Hirabayashi K; Saito S; Shigemura T; Tanaka M; Yanagisawa R; Sakashita K; Koike K
    Infection; 2014 Aug; 42(4):639-47. PubMed ID: 24567233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.
    Ikawa K; Nomura K; Morikawa N; Ikeda K; Taniwaki M
    J Antimicrob Chemother; 2009 Oct; 64(4):840-4. PubMed ID: 19700475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.